TransCode Therapeutics, Inc.

Stocks

RNAZ

US89357L5012

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
1.630 ^USD	-5.78%		-7.91%	-76.13%

10-29	TransCode Therapeutics, Inc. Engages Tungsten Advisors to Consider Strategic Options	CI
10-19	Transcode Therapeutics, Inc. Presents Phase 1A Clinical Trial Data for Ttx-Mc138 At Esmo Congress 2026	CI

Transcript : TransCode Therapeutics, Inc. - Special Call

Published on 06/18/2026 at 07:20 pm +03 - Modified on 06/18/2026 at 08:20 pm +03

S&P Capital IQ

Presenter Speech
Philippe Calais (Executives)

Good morning, everyone, and thank you very much for joining us for this first ever webcast to cover our company research and corporate strategy. I'm

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about TransCode Therapeutics, Inc.

10-29	TransCode Therapeutics, Inc. Engages Tungsten Advisors to Consider Strategic Options	CI
10-19	Transcode Therapeutics, Inc. Presents Phase 1A Clinical Trial Data for Ttx-Mc138 At Esmo Congress 2026	CI
10-13	Natera, Inc. and TransCode Therapeutics, Inc. Collaborate on Phase 2A Trial of TTX-MC138 in Colorectal Cancer	CI
10-13	Natera, TransCode Collaborate to Improve Enrollment for Colorectal Cancer Trial	MT
09-28	TransCode Therapeutics, Inc. Reports Updated Clinical Data from Its Phase 1A Clinical Trial of TTX-MC138	CI
09-22	TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology	CI
09-17	TransCode Therapeutics, Inc. - Special Call
09-10	Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 9, 2026	CI
09-10	Transcode Therapeutics, Inc. Announces Management Changes, Effective from September 9, 2026	CI
08-31	TransCode Therapeutics, Inc Announces Publication Demonstrating Survival Benefit Of TTX-MC138 In Preclinical Model Of Breast Cancer Bone Metastasis	CI
08-15	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-18	TransCode Therapeutics, Inc. - Special Call
06-03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT
06-03	Transcode Therapeutics Completes Phase 1A Clinical Trial and Advances Ttx-Mc138 to Phase 2A Development	CI
05-27	TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 In Patients With ctDNA Positive Colorectal Cancer	CI

Chart TransCode Therapeutics, Inc.

Duration

Period

RNAZ: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - TransCode Therapeutics, Inc.

More financial data